文献速递耳科与耳神经头颈外科

贝伐珠单抗用于2型神经纤维瘤病听力保留:侧重患者报告结局与毒性

Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
PubMed 文献 · Otolaryngol Head Neck Surg · 2018-10-30

本研究为病例系列,纳入17例接受贝伐珠单抗治疗听神经瘤的2型神经纤维瘤病患者(其中2例为维持人工耳蜗效果)。影像学阳性反应见于8/17(47%),中位肿瘤体积缩小19%;听力阳性反应见于5/9(56%),2例词识别得分提高超过40%;患者报告结局改善约40%。主要毒性包括高血压、蛋白尿、味觉障碍和闭经。

要点

  • 贝伐珠单抗可使47%的NF2患者肿瘤体积缩小,56%的患者听力改善。
  • 患者报告结局(如主观听力、耳鸣、沟通能力)改善约40%。
  • 需监测高血压、蛋白尿、味觉障碍和闭经等毒性。

核心结论

  • 贝伐珠单抗治疗后56%的患者听力改善,47%的患者肿瘤体积缩小,且患者报告结局有显著改善。

研究设计与样本

  • 病例系列研究,纳入17例连续接受贝伐珠单抗治疗的2型神经纤维瘤病患者,其中2例为维持人工耳蜗效果而治疗。

主要发现

  • 影像学阳性反应见于8/17(47%)患者,中位肿瘤体积缩小19%。
  • 听力阳性反应见于5/9(56%)患者,其中2例词识别得分提高超过40%。
  • 患者报告结局改善约40%。
  • 主要毒性包括高血压、蛋白尿、味觉障碍和闭经。

关键数值与推荐

  • 影像学阳性反应定义为8/17(47%)患者出现肿瘤体积缩小。
  • 听力阳性反应定义为5/9(56%)患者出现听力改善。
  • 词识别得分提高超过40%见于2例患者。

临床怎么用

  • 贝伐珠单抗可用于NF2患者听神经瘤的听力保留治疗。
  • 治疗期间需监测高血压、蛋白尿、味觉障碍和闭经等毒性。
  • 应关注患者报告结局,包括主观听力、耳鸣、眩晕、头痛、耳痛和电话沟通能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Bevacizumab for hearing preservation in patients with neurofibromatosis type 2 (NF2) is an emerging practice. We set out to characterize the effectiveness and toxicity of bevacizumab in our patient group. STUDY DESIGN: Case series with chart review. SETTING: Tertiary referral center. SUBJECTS AND METHODS: Seventeen consecutive patients with NF2 received bevacizumab treatment for vestibular schwannomas, including 2 patients treated to maintain cochlear implant performance. Volumetric analysis of serial magnetic resonance imaging scans was used to evaluate radiographic response, and hearing response was evaluated with serial audiograms. Patient-reported outcomes were also assessed, including subjective hearing improvement, changes in tinnitus, vertigo, headaches, ear pain, and improvement in ability to communicate via telephone. RESULTS: A positive radiographic response occurred in 8 of 17 (47%) patients and the median tumor volume change was a tumor decrease of 19%. A positive hearing response was recorded in 5 of 9 (56%) patients. Two patients had a word recognition score improvement over 40%. There was an approximately 40% improvement in patient-reported outcomes. Primary toxicities included hypertension, proteinuria, dysgeusia, and amenorrhea. CONCLUSION: Bevacizumab treatment was followed by hearing improvement in 56% of patients, while decreased tumor volume was noted in 47%. These outcomes agree favorably with prior reported series. There were significant improvements in patient-reported outcomes that have not been described previously.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Sverak P, Adams ME, Haines SJ, et al. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities. Otolaryngol Head Neck Surg. 2018. PMID: 30373466. doi:10.1177/0194599818809085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。